The global plasma medicine market size was valued at USD 32.4 billion in 2021 and is projected to reach USD 58.3 billion by 2030, registering a CAGR of 6.75% from 2022 to 2030.
Plasma medicine is a new field that combines plasma physics, biology, and clinical medicine. It has an effect on several important parts of patient care and is becoming more and more popular. In the past, plasmas were used in medicine to stop bleeding without touching it. They were also used in electrosurgery to stop bleeding. Non-thermal plasmas, on the other hand, are now used a lot in medicine because they are effective and don't harm biological systems.
Plasma technology is most often used to sterilize tissue, treat wounds and skin problems, regenerate tissue, and kill pathogens. Micro-plasmas, plasma jets, dielectric barrier discharges, capacitively or inductively coupled discharges, and inductively or capacitively coupled discharges are all ways that plasmas can be made for use in medical applications. These technologies change the way systems that use room-temperature air, gases, and liquids that work at low temperatures work.
Several commercial products have also been talked about because of the technology used, the health care problems that were solved, and the results of the clinical trials.
During the next few years, more and more products are expected to come out, which should help the global plasma medication market grow. For example, Grifols, S.A., the world's leading maker of plasma-based medicines, announced that albumin ALBUTEIN FlexBag (Albumin [Human] U.S.P.) will be available in November 2021. The product was available in both 5% and 25% concentrations. Plasma is where ALBUTEIN is made, and it is recommended that it be used in operations that involve cardiac bypass, low blood volume, low albumin levels, or exchanging plasma.
During the forecast period, the leading market players are expected to drive the market's growth by building more new plasma collection facilities. For example, in January 2022, ADMA Biologics, Inc., a commercial biopharmaceutical company that makes, markets, and develops specialty plasma-derived biologics, announced that it had received approval from the US Food and Drug Administration (FDA) for its fourth ADMA Bio-Centers plasma collection facility, which is in Goose Creek, South Carolina. This facility is part of the network of plasma collection centres run by ADMA Bio-Centers.
Two of the main things that stop the global market for plasma medicines from growing are the high cost of plasma medicines and the long amount of time it takes to make plasma medicines.
Plasma medicines are made with expensive technologies that use human plasma, which is a complicated raw material that must be collected from a lot of blood or plasma donors. This means that a large number of plasma donors need to be found. The price of these things is affected by a number of things, such as the complexity of the technologies used, the cost of the raw materials, and the safety measures that are taken to protect the consumer.
In the past ten years, plasma medicine has become a fast-growing area of research that is becoming more important. This research topic looks at how chemistry, plasma physics, biomedical sciences, and engineering can work together to create a lot of new opportunities. This is now possible because low-temperature plasma sources have been made and scientists have learned a lot about how complex plasma phenomena work.
This high-quality market intelligence also shows the current opportunities in the market. There is a lot of room for plasma medicine to be used in developing countries, there is a growing need for tools that don't require invasive surgery, and there is a need for a way to treat wound infections.
Based on Type, the market is segmented into Albumin, Coagulation Factor, Immunoglobulin, and Others.
Albumin is a protein that is found in the plasma part of the blood. It has many important jobs to do in the body. Some of these roles are moving hormones and other substances through the circulatory system, keeping oncotic pressure steady, and helping to control the amount of fluid in the body. About half of the protein in human blood plasma is made up of this. Low levels of albumin can cause a number of symptoms and diseases, such as edoema (also called swelling) and ascites (fluid accumulation in the abdomen).
The liver is in charge of making things that help blood clot. After that, they stay in the blood until they are needed again. When you get an injury or have surgery, your body needs more coagulation factors to help stop the bleeding. Even if you don't have surgery, this is still true. Some people have problems with how much coagulation factor is in their bodies. Because of this, their blood may not be able to clot as easily as usual, and they may bleed more than usual.
Immunoglobulin is a protein that is found in the blood and is a key part of how the body fights off infections. It works to treat a wide range of conditions, such as cancer, infections, and autoimmune diseases. Immunoglobulin can be made from plasma taken from either people or animals.
Hospitals, Clinics, and Others make up the different parts of the application market.
Plasma-made medicine is being used more and more in hospitals and medical clinics because it works well against a wide range of diseases. Plasma-based drugs are used to treat a wide range of bleeding disorders, such as von Willebrand disease, haemophilia, and others. They are also used to treat septic shock and burns, as well as acute respiratory distress syndrome (ARDS).
Medicines made from plasma are often used in hospitals and clinics to treat a wide range of illnesses. They are used to treat diseases like problems with the immune system, bleeding problems, and some types of cancer. Medicines made from plasma can also be used to treat people who have been exposed to certain poisons or viruses.
Based on Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
The plasma medicine market share is split into North America, Europe, Asia-Pacific, and LAMEA.
During the time period covered by this prediction, it is expected that plasma medicines will be most popular in North America. Most of the supremacy comes from the fact that more research and development is being done in the field and that the infrastructure is very well developed. In the years to come, the market is expected to grow even more thanks to good government rules and new therapies that have been approved by the FDA. The Food and Drug Administration (FDA) in the United States has asked people who have survived the COVID-19 pandemic to donate plasma. This is because the disease has spread so widely.
On the other hand, Europe has been able to get the second largest share of the market. This is because more people are getting rare diseases and more money is being put into plasma medicine, both of which are making the market in this area grow.
The Asia-Pacific market is expected to grow because countries like India and China are putting more money into finding new drugs and building up their healthcare research infrastructure.
During the forecast period, it is expected that the markets in Latin America, the Middle East, and Africa will grow at a slower rate. This is likely to be the case because fewer products are used for R&D activities and there isn't enough advanced lab infrastructure to make new products.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
January 2019 –Shire, one of Japan's leading biopharmaceutical companies, was acquired by Takeda Pharmaceutical Company Limited.
July 2021 - Octapharma AG, a company that develops and manufactures high-quality human proteins from human plasma and human cell lines, announced that the FDA had approved Octagam 10%, an immune globulin intravenous (human) liquid preparation derived from large pools of human plasma, as the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.
January 2022 - Bio Products Laboratory (BPL), a prominent developer of plasma-derived protein treatments, has been granted a license to market ALBUMINEX 25% in China by the National Medical Products Administration (NMPA).